Quantcast
Last updated on April 24, 2014 at 6:16 EDT

Latest Astellas Pharma Inc. Stories

2011-08-28 19:00:00

TOKYO, Aug. 28, 2011 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo:4503, "Astellas") today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron (generic name / code name: YM178) to the U.S. Food and Drug Administration and the European Medicines Agency. The submissions were sent on August 24 and 26, 2011 (Europe and US, respectively). Astellas is seeking approval for this first in a new class of medicine for the indication of overactive...

2011-08-09 07:00:00

SAN MATEO, Calif., Aug. 9, 2011 /PRNewswire/ -- Recent Highlights: Completed equity and debt financing totaling $40 million Qutenza® (capsaicin) 8% patch launch in U.S. building momentum in large U.S. institutions; 432 institutions purchased as of 2Q11, up 34% from 1Q11 Sales of Qutenza to end user customers increased 23% over 1Q11 2Q11 revenue totaled $2.5 million including $0.5 million U.S. Qutenza product revenue EU launch by Astellas advancing, with Qutenza...

2011-06-13 07:30:00

LONDON, June 13, 2011 /PRNewswire/ -- Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor. The study is evaluating AC220 as an oral, once-a-day, monotherapy treatment in acute myeloid leukemia (AML) in 240 patients with FLT3-ITD activating mutations who have relapsed or are refractory to other treatments, including chemotherapy and...

2011-06-09 07:16:00

SAN DIEGO and TOKYO, June 9, 2011 /PRNewswire-FirstCall/ -- Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that the first presentation of interim data from a global multi-center Phase 2 study evaluating the investigational drug AC220, a potent and selective FLT3 inhibitor. The data will be presented in an oral session at the upcoming European Hematology Association (EHA) meeting in London. The abstract (#1019) can be accessed at the EHA Congress website at...

2011-06-06 08:13:00

DEERFIELD, Ill., June 6, 2011 /PRNewswire/ -- Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, today announced that it will be presenting data from a phase II study evaluating AGS-1C4D4 in metastatic pancreatic cancer in a poster session at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago. The study was conducted at Agensys, Inc., a member of the Astellas global group of companies, which is developing a...

2011-05-19 12:00:00

DEERFIELD, Ill., May 19, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas") recently hired Mark Reisenauer as vice president of sales and marketing, oncology. Reporting directly to Patrick Shea, senior vice president of marketing & sales, Reisenauer will be responsible for all U.S. commercial activities supporting marketed products, the company's oncology co-promotion partners and will lead commercial planning for early stage development compounds. "Astellas has made...

2011-05-17 14:31:00

DEERFIELD, Ill., May 17, 2011 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas Pharma US"), U.S. subsidiary of Astellas Pharma Inc. (Tokyo: TSE: 4503, "the Company"), today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms - urinary incontinence (leakage of urine) and frequency of micturition...

2011-05-03 08:30:00

DEERFIELD, Ill., May 3, 2011 /PRNewswire/ -- Astellas Pharma Global Development, Inc. ("APGD"), a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, welcomes four seasoned industry leaders to its team. New additions include Stephen Eck, M.D., Ph.D. as vice president, head of medical oncology, Karen Reeves, M.D. as vice president, global head of medical science, Mark Weinberg, M.D., MBA as therapeutic area head for central nervous system (CNS) and pain and Bernhardt Zeiher, M.D. as...

2011-04-29 06:05:00

SAN MATEO, Calif., April 29, 2011 /PRNewswire/ -- First Quarter 2011 Highlights: Qutenza® (capsaicin) 8% patch purchased by 321 institutions, up from 239 in Q4 2010 Revenue of $3.2 million including $0.6 million U.S. Qutenza product revenue Operational focus enables lower planned expense growth in 2011 Qutenza sales initiated in Poland and Czech Republic by Astellas NGX-1998 Phase 2 clinical trial continues in postherpetic neuralgia (PHN) patients surpassing 65%...

2011-04-29 06:00:00

SAN MATEO, Calif., April 29, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that long time CEO Anthony DiTonno will retire by December 31, 2011. The Board of Directors has initiated a formal executive search for a Chief Executive Officer. Anthony DiTonno commented, "I have been CEO of NeurogesX for more than eight years and we have accomplished the objectives I...